Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients | Zendy

R. Rautemaa | Zendy; Malcolm Richardson | Zendy; Michael A. Pfaller | Zendy; P. Koukila-Kahkola | Zendy; Jaakko Perheentupa | Zendy; Harri Saxén | Zendy

Open Access

Decreased susceptibility of Candida albicans to azole antifungals: a complication of long-term treatment in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients

Author(s) -

R. Rautemaa,

Malcolm Richardson,

Michael A. Pfaller,

P. Koukila-Kahkola,

Jaakko Perheentupa,

Harri Saxén

Publication year - 2007

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkm299

Subject(s) - medicine , azole , chronic mucocutaneous candidiasis , mycosis , complication , dystrophy , candida albicans , fluconazole , antifungal , dermatology , refractory (planetary science) , gastroenterology , disease , immunology , pathology , biology , microbiology and biotechnology , astrobiology

Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED, APS1) is an autosomal recessive disease exceptionally common in Finland. Most patients have chronic oral candidiasis from early childhood and this infection has been shown to be carcinogenic. Hence, patients receive repeated treatment and prophylactic courses of antifungals throughout life. In Finland, 92 patients have been diagnosed with APECED and 66 of them are currently alive. Our aim was to study the effect of long-term azole treatment on the candidal colonization of APECED patients and the influence on antifungal susceptibilities.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research